Copyright Reports & Markets. All rights reserved.

Global Next Generation Antibody Therapeutics Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Next Generation Antibody Therapeutics Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Antibody Drug Conjugates (ADCs)
    • 1.4.3 Bispecific Antibodies (BsAbs)
    • 1.4.4 Fc Engineered Antibodies
    • 1.4.5 Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
    • 1.4.6 Biosimilar Antibody (Ab) Products
  • 1.5 Market by Application
    • 1.5.1 Global Next Generation Antibody Therapeutics Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospitals
    • 1.5.3 Clinics
    • 1.5.4 Others
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends

  • 2.1 Global Next Generation Antibody Therapeutics Market Perspective (2015-2026)
  • 2.2 Global Next Generation Antibody Therapeutics Growth Trends by Regions
    • 2.2.1 Next Generation Antibody Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Next Generation Antibody Therapeutics Historic Market Share by Regions (2015-2020)
    • 2.2.3 Next Generation Antibody Therapeutics Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Next Generation Antibody Therapeutics Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Next Generation Antibody Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Next Generation Antibody Therapeutics Players by Market Size
    • 3.1.1 Global Top Next Generation Antibody Therapeutics Players by Revenue (2015-2020)
    • 3.1.2 Global Next Generation Antibody Therapeutics Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Next Generation Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Next Generation Antibody Therapeutics Market Concentration Ratio
    • 3.2.1 Global Next Generation Antibody Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Next Generation Antibody Therapeutics Revenue in 2019
  • 3.3 Next Generation Antibody Therapeutics Key Players Head office and Area Served
  • 3.4 Key Players Next Generation Antibody Therapeutics Product Solution and Service
  • 3.5 Date of Enter into Next Generation Antibody Therapeutics Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Next Generation Antibody Therapeutics Historic Market Size by Type (2015-2020)
  • 4.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

  • 5.1 Global Next Generation Antibody Therapeutics Market Size by Application (2015-2020)
  • 5.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Next Generation Antibody Therapeutics Market Size (2015-2020)
  • 6.2 Next Generation Antibody Therapeutics Key Players in North America (2019-2020)
  • 6.3 North America Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
  • 6.4 North America Next Generation Antibody Therapeutics Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Next Generation Antibody Therapeutics Market Size (2015-2020)
  • 7.2 Next Generation Antibody Therapeutics Key Players in Europe (2019-2020)
  • 7.3 Europe Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
  • 7.4 Europe Next Generation Antibody Therapeutics Market Size by Application (2015-2020)

8 China

  • 8.1 China Next Generation Antibody Therapeutics Market Size (2015-2020)
  • 8.2 Next Generation Antibody Therapeutics Key Players in China (2019-2020)
  • 8.3 China Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
  • 8.4 China Next Generation Antibody Therapeutics Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Next Generation Antibody Therapeutics Market Size (2015-2020)
  • 9.2 Next Generation Antibody Therapeutics Key Players in Japan (2019-2020)
  • 9.3 Japan Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
  • 9.4 Japan Next Generation Antibody Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Next Generation Antibody Therapeutics Market Size (2015-2020)
  • 10.2 Next Generation Antibody Therapeutics Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Next Generation Antibody Therapeutics Market Size by Application (2015-2020)

11 India

  • 11.1 India Next Generation Antibody Therapeutics Market Size (2015-2020)
  • 11.2 Next Generation Antibody Therapeutics Key Players in India (2019-2020)
  • 11.3 India Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
  • 11.4 India Next Generation Antibody Therapeutics Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Next Generation Antibody Therapeutics Market Size (2015-2020)
  • 12.2 Next Generation Antibody Therapeutics Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
  • 12.4 Central & South America Next Generation Antibody Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Pfizer
    • 13.1.1 Pfizer Company Details
    • 13.1.2 Pfizer Business Overview
    • 13.1.3 Pfizer Next Generation Antibody Therapeutics Introduction
    • 13.1.4 Pfizer Revenue in Next Generation Antibody Therapeutics Business (2015-2020))
    • 13.1.5 Pfizer Recent Development
  • 13.2 Roche
    • 13.2.1 Roche Company Details
    • 13.2.2 Roche Business Overview
    • 13.2.3 Roche Next Generation Antibody Therapeutics Introduction
    • 13.2.4 Roche Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
    • 13.2.5 Roche Recent Development
  • 13.3 Bristol-Myers Squibb
    • 13.3.1 Bristol-Myers Squibb Company Details
    • 13.3.2 Bristol-Myers Squibb Business Overview
    • 13.3.3 Bristol-Myers Squibb Next Generation Antibody Therapeutics Introduction
    • 13.3.4 Bristol-Myers Squibb Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
    • 13.3.5 Bristol-Myers Squibb Recent Development
  • 13.4 Amgen
    • 13.4.1 Amgen Company Details
    • 13.4.2 Amgen Business Overview
    • 13.4.3 Amgen Next Generation Antibody Therapeutics Introduction
    • 13.4.4 Amgen Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
    • 13.4.5 Amgen Recent Development
  • 13.5 AstraZeneca
    • 13.5.1 AstraZeneca Company Details
    • 13.5.2 AstraZeneca Business Overview
    • 13.5.3 AstraZeneca Next Generation Antibody Therapeutics Introduction
    • 13.5.4 AstraZeneca Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
    • 13.5.5 AstraZeneca Recent Development
  • 13.6 Bayer
    • 13.6.1 Bayer Company Details
    • 13.6.2 Bayer Business Overview
    • 13.6.3 Bayer Next Generation Antibody Therapeutics Introduction
    • 13.6.4 Bayer Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
    • 13.6.5 Bayer Recent Development
  • 13.7 Takeda Pharmaceuticals
    • 13.7.1 Takeda Pharmaceuticals Company Details
    • 13.7.2 Takeda Pharmaceuticals Business Overview
    • 13.7.3 Takeda Pharmaceuticals Next Generation Antibody Therapeutics Introduction
    • 13.7.4 Takeda Pharmaceuticals Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
    • 13.7.5 Takeda Pharmaceuticals Recent Development
  • 13.8 Biogen
    • 13.8.1 Biogen Company Details
    • 13.8.2 Biogen Business Overview
    • 13.8.3 Biogen Next Generation Antibody Therapeutics Introduction
    • 13.8.4 Biogen Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
    • 13.8.5 Biogen Recent Development
  • 13.9 Seattle Genetics
    • 13.9.1 Seattle Genetics Company Details
    • 13.9.2 Seattle Genetics Business Overview
    • 13.9.3 Seattle Genetics Next Generation Antibody Therapeutics Introduction
    • 13.9.4 Seattle Genetics Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
    • 13.9.5 Seattle Genetics Recent Development
  • 13.10 ImmunoGen
    • 13.10.1 ImmunoGen Company Details
    • 13.10.2 ImmunoGen Business Overview
    • 13.10.3 ImmunoGen Next Generation Antibody Therapeutics Introduction
    • 13.10.4 ImmunoGen Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
    • 13.10.5 ImmunoGen Recent Development
  • 13.11 Kyowa Hakko Kirin
    • 10.11.1 Kyowa Hakko Kirin Company Details
    • 10.11.2 Kyowa Hakko Kirin Business Overview
    • 10.11.3 Kyowa Hakko Kirin Next Generation Antibody Therapeutics Introduction
    • 10.11.4 Kyowa Hakko Kirin Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
    • 10.11.5 Kyowa Hakko Kirin Recent Development
  • 13.12 Xencor
    • 10.12.1 Xencor Company Details
    • 10.12.2 Xencor Business Overview
    • 10.12.3 Xencor Next Generation Antibody Therapeutics Introduction
    • 10.12.4 Xencor Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
    • 10.12.5 Xencor Recent Development
  • 13.13 Dyax Corp
    • 10.13.1 Dyax Corp Company Details
    • 10.13.2 Dyax Corp Business Overview
    • 10.13.3 Dyax Corp Next Generation Antibody Therapeutics Introduction
    • 10.13.4 Dyax Corp Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
    • 10.13.5 Dyax Corp Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Next Generation Antibody Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Next Generation Antibody Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    The key players covered in this study
    Pfizer
    Roche
    Bristol-Myers Squibb
    Amgen
    AstraZeneca
    Bayer
    Takeda Pharmaceuticals
    Biogen
    Seattle Genetics
    ImmunoGen
    Kyowa Hakko Kirin
    Xencor
    Dyax Corp

    Market segment by Type, the product can be split into
    Antibody Drug Conjugates (ADCs)
    Bispecific Antibodies (BsAbs)
    Fc Engineered Antibodies
    Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
    Biosimilar Antibody (Ab) Products
    Market segment by Application, split into
    Hospitals
    Clinics
    Others

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    Buy now